Shire Pharmaceuticals has just achieved another victory in the enforcement of its Lialda® patent.
On January 27, 2017, the United District Court for the Middle District of Florida issued an opinion in Shire Development LLC v. Mylan Pharmaceuticals, Inc., finding infringement of United States Patent No. 6,773,720 (the '720 patent) by defendant Mylan's proposed generic version of Lialda®. The Court entered a final judgment accordingly, enjoining the Mylan defendants from making, using, selling or importing its product into the United States and dismissing its counterclaims of invalidity with prejudice.
Plaintiffs Shire Development LLC, Shire Pharmaceutical Development Inc., Cosmo Technologies Ltd., and Nogra Pharma were represented by Ed Haug, Elizabeth Murphy, Jason Lief, Angus Chen, and Andrew Wasson, all from the firm of Frommer Lawrence & Haug LLP.
If you would like to view the decision, please click here.
If you want to view the Law360 article, please click here.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
